Bachem brings peptide partnering opportunities to BIO-Europe Spring Vienna

Bachem brings peptide partnering opportunities to BIO-Europe Spring Vienna

Bachem 150 x 42

News | Bachem AG

MARCH 14, 2019

Bubendorf, Switzerland: –‘Pioneering Partner for Peptides’ Bachem AG will be presenting its expanded portfolio of CMO capabilities in peptide-based active pharmaceutical ingredients (APIs) and innovative selective glycosylation processes at one of Europe’s premier biotech networking conferences in Vienna later this month.

Bachem will also be an exhibitor at the EBD Group’s annual BIO-Europe Spring biotech industry partnering conference, this year in Vienna.

CMO for peptide APIs

The Bachem stand at Booth 2 in Hall A of the Messe Wien Exhibition and Congress Center will focus on its innovative portfolio of small molecule APIs and proprietary processes that harness its outstanding knowledge of peptide and carbohydrate chemistry.

Recently, Bachem’s award-winning single glycosylation process has enabled production scale chemical synthesis of Interferon β-1a, along with custom manufacturing, synthetic organic chemistry, generic peptidic and small molecule.

About Bachem

The Bachem Group is the world’s only full service provider of peptides and provides a full range of other services to the pharma and biotech industries.

Under its banner Pioneering Partner for Peptides, Bachem specializes in the process development and manufacture of peptides and complex organic molecules as active pharmaceutical ingredients (APIs).

A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.

Headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.

Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.

Bachem has six production sites in the U.S. and in Europe along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, new chemical entities (NCEs) and finished dosage forms at preclinical, clinical and production scales.

About BIO-Europe Spring 2019

BIO-Europe Spring® a premier partnering conference that annually attracts an international “who’s who” from biotech, pharma and finance for high caliber networking.

The three-day event opens on March 25 at the Messe Wien Exhibition and Congress Center in Vienna.

Featuring EBD Group’s sophisticated partnering system, partneringONE®, the event enables delegates to network with companies across the life science value chain, from large biotech and pharma companies to financiers and innovators.

The conference is expected to attract some 2,500 delegates and 70 exhibitors representing more than 1,400 companies from some 50 countries worldwide. It will feature more than 20 workshops and panels with more than 3,600 licensing opportunities posted.

The event is organized by EBD with more information at:

Media Contact

Dr. Martina Diekmann, Vice-President, Global Marketing, Bachem Group
Tel: +41 799 459 107


Click on Bachem at BIO-Europe Spring Vienna for more information.
Click on
Bachem to contact the company directly.

Supplier Information
Supplier: Bachem AG
Address: Hauptstrasse 144, 4416 Bubendorf, Switzerland
Tel: +41 61 935 2323
Fax: +41 61 935 2325

Comments are closed.